CA2273946A1 - Ligand radiomarque servant a introduire selectivement un radionucleide emetteur d'electrons auger dans le noyau d'une cellule cancereuse - Google Patents
Ligand radiomarque servant a introduire selectivement un radionucleide emetteur d'electrons auger dans le noyau d'une cellule cancereuse Download PDFInfo
- Publication number
- CA2273946A1 CA2273946A1 CA002273946A CA2273946A CA2273946A1 CA 2273946 A1 CA2273946 A1 CA 2273946A1 CA 002273946 A CA002273946 A CA 002273946A CA 2273946 A CA2273946 A CA 2273946A CA 2273946 A1 CA2273946 A1 CA 2273946A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- ligand
- hegf
- cells
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Cette invention se rapporte à un ligand radiomarqué qui permet d'introduire un radionucléide émetteur d'électrons Auger dans le noyau d'une cellule cancéreuse. Ce ligand se lie spécifiquement à un récepteur de surface cellulaire qui est unique à une cellule cancéreuse ou qui est surexprimé sur une cellule cancéreuse. Un radionucléide émetteur d'électrons Auger se lie au ligand soit directement soit par l'intermédiaire d'un chélateur. Le ligand radiomarqué est internalisé par la cellule lors de la liaison au récepteur, et une partie suffisante des ligands ainsi internalisés est transportée jusqu'au noyau, afin d'appliquer sur celui-ci une dose de rayonnement l'étale.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75928296A | 1996-12-02 | 1996-12-02 | |
| US08/759,282 | 1996-12-02 | ||
| PCT/CA1997/000909 WO1998024481A2 (fr) | 1996-12-02 | 1997-12-01 | Ligand radiomarque servant a introduire selectivement un radionucleide emetteur d'electrons auger dans le noyau d'une cellule cancereuse |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2273946A1 true CA2273946A1 (fr) | 1998-06-11 |
Family
ID=25055081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002273946A Abandoned CA2273946A1 (fr) | 1996-12-02 | 1997-12-01 | Ligand radiomarque servant a introduire selectivement un radionucleide emetteur d'electrons auger dans le noyau d'une cellule cancereuse |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU5113198A (fr) |
| CA (1) | CA2273946A1 (fr) |
| WO (1) | WO1998024481A2 (fr) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE120374T1 (de) * | 1989-07-20 | 1995-04-15 | Sandoz Ag | Markierte polypeptidderivate. |
-
1997
- 1997-12-01 AU AU51131/98A patent/AU5113198A/en not_active Abandoned
- 1997-12-01 CA CA002273946A patent/CA2273946A1/fr not_active Abandoned
- 1997-12-01 WO PCT/CA1997/000909 patent/WO1998024481A2/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998024481A3 (fr) | 2001-12-20 |
| AU5113198A (en) | 1998-06-29 |
| WO1998024481A2 (fr) | 1998-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reilly et al. | 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR | |
| Jain et al. | Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors | |
| Choi et al. | Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation | |
| Dadachova et al. | The Na+/I− symporter (NIS): imaging and therapeutic applications | |
| Krall et al. | A 99mTc-labeled ligand of carbonic anhydrase IX selectively targets renal cell carcinoma in vivo | |
| Slastnikova et al. | Modular nanotransporters: a versatile approach for enhancing nuclear delivery and cytotoxicity of Auger electron-emitting 125 I | |
| Zitzmann et al. | A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy | |
| Rasaneh et al. | Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer | |
| Wu et al. | Development of theranostic active-targeting boron-containing gold nanoparticles for boron neutron capture therapy (BNCT) | |
| bin Othman et al. | In vitro cytotoxicity of Auger electron-emitting [67Ga] Ga-trastuzumab | |
| Tian et al. | External imaging of CCND1 cancer gene activity in experimental human breast cancer xenografts with 99mTc-peptide-peptide nucleic acid-peptide chimeras | |
| Rosenkranz et al. | Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to α-particle emitting 211At | |
| JP2008517917A (ja) | 癌を治療するための毒素および放射性核種結合ｉｇｆ−１受容体リガンド | |
| Tian et al. | PET imaging of CCND1 mRNA in human MCF7 estrogen receptor–positive breast cancer xenografts with oncogene-specific [64Cu] chelator-peptide nucleic acid-IGF1 analog radiohybridization probes | |
| Capala et al. | Radiolabeling of epidermal growth factor with 99mTc and in vivo localization following intracerebral injection into normal and glioma-bearing rats | |
| Tian et al. | External imaging of CCND1, MYC, and KRAS oncogene mRNAs with tumor‐targeted radionuclide‐PNA‐peptide chimeras | |
| Tian et al. | Noninvasive Molecular Imaging of MYC mRNA Expression in Human Breast Cancer Xenografts with a [99mTc] Peptide− Peptide Nucleic Acid− Peptide Chimera | |
| Deutscher et al. | Tumor targeting and SPECT imaging properties of an 111In-labeled galectin-3 binding peptide in prostate carcinoma | |
| Deshayes et al. | Radiolabeled antibodies against müllerian-inhibiting substance receptor, type II: new tools for a theranostic approach in ovarian cancer | |
| Lymperis et al. | Comparative evaluation of the new GRPR‐antagonist 111In‐SB9 and 111In‐AMBA in prostate cancer models: Implications of in vivo stability | |
| CA2189051C (fr) | Composition destinee a l'apport de radio-isotopes toxiques au noyau de la cellule, et son utilisation | |
| TWI602577B (zh) | 雙重標靶融合蛋白 | |
| Raza Naqvi et al. | Insertion of a lysosomal enzyme cleavage site into the sequence of a radiolabeled neuropeptide influences cell trafficking in vitro and in vivo | |
| Wang et al. | Amplified delivery of indium-111 to EGFR-positive human breast cancer cells | |
| CA2273946A1 (fr) | Ligand radiomarque servant a introduire selectivement un radionucleide emetteur d'electrons auger dans le noyau d'une cellule cancereuse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |